Donald J. Graham

3.8k citations

31 papers · 2.0k indexed · 1 hit paper · h-index 19

Co-authors: Jon H. Condra Emilio A. Emini L Gotlib William A. Schleif H.L. Robbins Kathleen Squires Lori J. Gabryelski J C Quintero
Topics: HIV/AIDS drug development and treatment (19 papers)Hepatitis C virus research (14 papers)HIV Research and Treatment (13 papers)
Cited by: Virology Infectious Diseases Hepatology
Journals: Nature Proceedings of the National Academy of Sciences Journal of Biological Chemistry
Partner nations: United States Italy Argentina

In The Last Decade

Donald J. Graham

30 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

1995 810 citations Jon H. Condra, William A. Schleif et al. Nature profile →

Peers

Countries citing papers authored by Donald J. Graham

Since Specialization

Citations

This map shows the geographic impact of Donald J. Graham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Donald J. Graham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Donald J. Graham more than expected).

Fields of papers citing papers by Donald J. Graham

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Donald J. Graham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Donald J. Graham. The network helps show where Donald J. Graham may publish in the future.

Co-authorship network of co-authors of Donald J. Graham

This figure shows the co-authorship network connecting the top 25 collaborators of Donald J. Graham. A scholar is included among the top collaborators of Donald J. Graham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Donald J. Graham. Donald J. Graham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal 2017 ·JCI Insight ·Guoxin Wu,Michael D. Swanson,Aarthi Talla,Donald J. Graham,Julie Strizki,Daniel M. Gorman,Richard J. O. Barnard,Wade Blair,Ole S. Søgaard,Martin Tolstrup,Lars Østergaard,Thomas A. Rasmussen,Rafick‐Pierre Sékaly,Nancie M. Archin,David M. Margolis,Daria J. Hazuda,Bonnie J. Howell	50
2	Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment-experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: A population and clonal analysis 2013 ·Virology ·Richard J. O. Barnard,Carolyn McHale,(unknown),(unknown),Donald J. Graham,(unknown),Julie Strizki,Peggy Hwang,(unknown),Jacqueline D. Reeves,David C. Nickle,Mark J. DiNubile,Daria J. Hazuda,Niloufar Mobashery	18
3	Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3 2013 ·Journal of Hepatology ·Marcelo Silva,Michelle Treitel,Donald J. Graham,Stephanie Curry,(unknown),Patricia McMonagle,Samir K. Gupta,Eric Hughes,Robert A. Chase,Frederick Lahser,Richard J. O. Barnard,Anita Y. M. Howe,John A. Howe	35
4	Discovery of MK‐8742: An HCV NS5A Inhibitor with Broad Genotype Activity 2013 ·ChemMedChem ·Craig A. Coburn,Peter T. Meinke,Wei Chang,Christine Fandozzi,Donald J. Graham,Bin Hu,Qian Huang,Stacia Kargman,Joseph A. Kozlowski,Rong Liu,John A. McCauley,Amin A. Nomeir,Richard Söll,Joseph P. Vacca,Dahai Wang,Hao Wu,Bin Zhong,David B. Olsen,Steven W. Ludmerer	143
5	844 IN VITRO CHARACTERIZATION OF THE PAN-GENOTYPE ACTIVITY OF THE HCV NS3/4A PROTEASE INHIBITORS BOCEPREVIR AND TELAPREVIR 2012 ·Journal of Hepatology ·John A. Howe,Donald J. Graham,Patricia McMonagle,Stephanie Curry,Robert A. Chase,Frederick Lahser,Robert A. Ogert,Julie Strizki,(unknown),(unknown),(unknown),Michelle Treitel,Daria J. Hazuda,A Howe	2
6	Structural Basis for Resistance of the Genotype 2b Hepatitis C Virus NS5B Polymerase to Site A Non-Nucleoside Inhibitors 2009 ·Journal of Molecular Biology ·Edwin H. Rydberg,Antonella Cellucci,Linda Bartholomew,Marco Mattu,Gaetano Barbato,Steven W. Ludmerer,Donald J. Graham,Sergio Altamura,Giacomo Paonessa,Raffaele De Francesco,Giovanni Migliaccio,Andrea Carfı́	15
7	A transient cell-based phenotype assay for hepatitis C NS3/4A protease: Application to potency determinations of a novel macrocyclic inhibitor against diverse protease sequences isolated from plasma infected with HCV 2008 ·Journal of Virological Methods ·Steven W. Ludmerer,Donald J. Graham,Mihir Patel,Kevin F. Gilbert,Mark W. Stahlhut,David B. Olsen	13
8	Evaluation of MK-7009, A Novel Macrocyclic Inhibitor of NS3/4A Protease, in the Chimpanzee Model of Chronic Hepatitis C Virus Infection 2008 ·Antiviral Research ·(unknown),Donald J. Graham,L K Handt,Christine Fandozzi,Christine Burlein,Nigel J. Liverton,John A. McCauley,Joseph P. Vacca,Daria J. Hazuda,Steven S. Carroll,David B. Olsen	2
9	A genotype 2b NS5B polymerase with novel substitutions supports replication of a chimeric HCV 1b:2b replicon containing a genotype 1b NS3-5A background 2005 ·Antiviral Research ·Donald J. Graham,Mark W. Stahlhut,Osvaldo Flores,David B. Olsen,Daria J. Hazuda,Robert L. LaFemina,Steven W. Ludmerer	13
10	Treatment with Indinavir, Efavirenz, and Adefovir after Failure of Nelfinavir Therapy 2003 ·The Journal of Infectious Diseases ·Alfred J. Saah,David W. Haas,Mark J. DiNubile,Joshua Chen,Daniel Holder,Rand R. Rhodes,(unknown),Kalpana Bakshi,Robert M. Danovich,Donald J. Graham,Jon H. Condra	11
11	Identification of a Key Determinant of Hepatitis C Virus Cell Culture Adaptation in Domain II of NS3 Helicase 2003 ·Journal of Biological Chemistry ·Jay A. Grobler,Eric Markel,John F. Fay,Donald J. Graham,(unknown),(unknown),Edward M. Murray,Giovanni Migliaccio,Osvaldo Flores	42
12	In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsbreakdown → 1995 ·Nature ·Jon H. Condra,William A. Schleif,(unknown),Lori J. Gabryelski,Donald J. Graham,J C Quintero,(unknown),H.L. Robbins,Elizabeth Röth,(unknown),(unknown),T. Yang,(unknown),Kathleen Squires,Paul Deutsch,Emilio A. Emini	810
13	Purification and Characterization of HIV-1 Reverse Transcriptase Having a 1:1 Ratio of p66 and p51 Subunits 1994 ·Protein Expression and Purification ·Mark W. Stahlhut,(unknown),Jon H. Condra,Jing-Li Fu,L Gotlib,Donald J. Graham,David B. Olsen	9
14	Human Immunodeficiency Virus Type 1 Protease Inhibitors: Evaluation of Resistance Engendered by Amino Acid Substitutions in the Enzyme's Substrate Binding Site 1994 ·Biochemistry ·Vinod Sardana,A J Schlabach,Pia Graham,Bruce L. Bush,Jon H. Condra,J. Chris Culberson,L Gotlib,Donald J. Graham,Nancy E. Kohl	42
15	Inhibition of HIV-1 reverse transcriptase by pyridinone derivatives. Potency, binding characteristics, and effect of template sequence. 1993 ·Journal of Biological Chemistry ·Steve S. Carroll,David B. Olsen,Carl D. Bennett,L Gotlib,Donald J. Graham,Jon H. Condra,Andrew M. Stern,Jules A. Shafer,Lawrence C. Kuo	41
16	Domains 1 and 2 of ICAM-1 are sufficient to bind human rhinoviruses 1992 ·Virus Research ·D W Lineberger,(unknown),Donald J. Graham,Richard J. Colonno	9
17	Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors. 1992 ·Journal of Biological Chemistry ·Vinod Sardana,Emilio A. Emini,L Gotlib,Donald J. Graham,D W Lineberger,William J. Long,A J Schlabach,Jill Wolfgang,Jon H. Condra	95
18	Bacterial expression of antibody fragments that block human rhinovirus infection of cultured cells. 1990 ·Journal of Biological Chemistry ·Jon H. Condra,Vinod Sardana,Joanne E. Tomassini,A J Schlabach,M E Davies,D W Lineberger,Donald J. Graham,L Gotlib,Richard J. Colonno	43
19	Sequence-specific interaction of Tat protein and Tat peptides with the transactivation-responsive sequence element of human immunodeficiency virus type 1 in vitro. 1990 ·Proceedings of the National Academy of Sciences ·Michael G. Cordingley,Robert L. LaFemina,P L Callahan,Jon H. Condra,Vinod Sardana,Donald J. Graham,(unknown),(unknown),L Gotlib,A J Schlabach	161
20	Macrophages in immunity to syphilis: suppressive effect of concurrent infection with Mycobacterium bovis BCG on the development of syphilitic lesions and growth of Treponema pallidum in tuberculin-positive rabbits 1979 ·Infection and Immunity ·Paul H. Hardy,Donald J. Graham,E. Ellen Nell,Arthur M. Dannenberg	11

About Donald J. Graham

Donald J. Graham is a scholar working on Virology, Hepatology and Infectious Diseases, having authored 31 papers that have together received 2.0k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (19 papers), Hepatitis C virus research (14 papers) and HIV Research and Treatment (13 papers). The work is most often cited by research in Virology (1.2k citations), Infectious Diseases (1.4k citations) and Hepatology (590 citations). Donald J. Graham has collaborated with scholars based in United States, Italy and Argentina. Frequent co-authors include Jon H. Condra, Emilio A. Emini, L Gotlib, William A. Schleif, H.L. Robbins, Kathleen Squires, Lori J. Gabryelski, J C Quintero, Paul Deutsch and T. Yang. Their work appears in journals such as Nature, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact